Corneal health sustained 3 years after iStent inject implantation

Researchers observed no additional risk to corneal endothelial safety beyond that of cataract surgery alone in 3-year data after iStent inject implantation.
This is “particularly relevant in light of concerning ECD outcomes seen with other MIGS devices,” according to a presentation at the virtual American Society of Cataract and Refractive Surgery meeting.
Using data from patients enrolled in the pivotal trial for the iStent inject (Glaukos), Thomas W. Samuelson, MD, and colleagues looked at endothelial eye health after 3 years, as well as patient-reported outcomes (PROs) over the

Full Story →